ClinicalTrials.gg
CompletedNCT01069900MOXIPEDIAUpdated Mar 20, 2018Results posted

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

A Phase 3 interventional study of Moxifloxacin (Avelox, BAY12-8039) and Ertapenem in Intraabdominal Infections, sponsored by Bayer. Completed at 39 sites in 16 countries. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2018-03-20.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
3 Months to 17 Years
Sex
All
01

Study summary

The primary focus of the study is the evaluation of the safety of treatment with moxifloxacin in a pediatric population 3 months to \<18 years old. Approximately 450 pediatric subjects with a complicated intra-abdominal infection will be enrolled in the study and treated with either moxifloxacin intravenously and orally if switched to oral therapy or ertapenem (intravenously) and, if switched to oral therapy, amoxicillin/clavulanate.

02

Conditions studied

  • Intraabdominal Infections

Keywords

  • Intra-abdominal infection
  • Pediatric infection
03

In context

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

This study's enrollment of 458 is above the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.

Browse Intraabdominal Infections studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized males or females 3 months to 17 years of age
  • Able to obtain parental or legal guardian written and assent from subjects as applicable by local laws and regulations
  • Expected duration of treatment with antibiotics is a minimum of 3 days administered IV, for a total of 5 to 14 days administered IV or IV followed by PO
  • If the subject is a female of she must have a negative pregnancy test at the screening visit or be capable of practicing an adequate method of , and agree to continue the same method for 1 month following the TOC visit. Lactating subjects are not to be included.
  • Subjects may be enrolled upon a surgically (laparotomy, laparoscopy, or percutaneous drainage) confirmed cIAI revealing at least one of the following:

    • Gross peritoneal inflammation with purulent exudate within the abdominal cavity
    • Intra-abdominal abscess
    • Macroscopic intestinal perforation with diffuse peritonitis OR
  • Subjects may be enrolled on the basis of a suspected cIAI, which must be supported with radiological evidence (ultrasound, abdominal plain films, computed tomography [CT], magnetic resonance imaging [MRI]) of gastrointestinal perforation or localized collections of potentially infected material and at least one of the following:

    • Symptoms referable to the abdominal cavity (eg, anorexia, nausea, vomiting or pain)
    • Tenderness (with or without rebound), involuntary guarding, absent or diminished bowel sounds, or abdominal wall rigidity
    • Fever
    • Leukocytosis
  • The subject must be scheduled for a surgical procedure (laparotomy or laparoscopy) or percutaneous drainage.

Exclusion criteria

Exclusion Criteria:

  • Presumed spontaneous bacterial peritonitis
  • All pancreatic processes including pancreatic sepsis, peripancreatic sepsis, or an cIAI secondary to pancreatitis
  • Early acute or suppurative (nonperforated) appendicitis unless there is evidence of an abscess or peritoneal fluid containing pus and micro-organisms suggestive of regional contamination
  • Infections originating from the female genital tract
  • Known severe . Subjects with known mild immunosuppression (eg, Type I or II diabetes mellitus, trauma, or [ANC] between 1000 and 1500 cells/mm3) may be enrolled.
  • Congenital or documented acquired
  • Receiving concomitant treatment with QT prolonging drugs
  • History of tendon disease/disorder related to quinolone treatment
  • Pathogenic organisms suspected or identified (eg, Pseudomonas) which are resistant to any of the study drugs
  • Abnormal musculoskeletal findings at baseline assessment; or chronic musculoskeletal disease (eg, juvenile rheumatoid arthritis); or chronic illness with high risk for chronic or recurrent arthritis or tendinitis (eg, cystic fibrosis, chronic inflammatory bowel disease)
  • History of myasthenia gravis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    Moxifloxacin (Avelox, BAY12-8039)

    Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride \[NaCl solution\]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.

    Drug: Moxifloxacin (Avelox, BAY12-8039) · Drug: Ertapenem placebo · Drug: Amoxicillin/Clavulanate placebo

  • Active comparator
    Comparator Ertapenem

    Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.

    Drug: Ertapenem · Drug: Amoxicillin/Clavulanate · Drug: Moxifloxacin placebo

Interventions

  • For subjects 12 to less than (\<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to \< 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to \< 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.

  • For subjects 13 to \<18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to \< 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.

  • DrugAmoxicillin/Clavulanate

    Drug pages: Amoxicillin · Clavulanic Acid

    Subjects 2 years to \< 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).

  • DrugMoxifloxacin placebo

    Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.

  • DrugErtapenem placebo

    Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.

  • DrugAmoxicillin/Clavulanate placebo

    Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events

    An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.

  2. Number of Subjects With Clinical Cardiac Adverse Events

    Time frame: Clinical cardiac event related to QT interval were recorded from treatment start until day 3 of treatment. All other clinical cardiac events were recorded from treatment start to test of cure visit, up to day 56.

  3. Number of Subjects With Musculoskeletal Adverse Events

    Time frame: All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.

Secondary outcomes

  1. Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term

    Musculoskeletal adverse events were classified as following SOCs (preferred terms): "injury, poisoning and procedural complications" (forearm fracture, joint injury, ligament sprain, muscle strain) "musculoskeletal and connective tissue disorders" (arthralgia, joint swelling, musculoskeletal pain, myalgia). Incidence rates were reported as percentage of subjects categorized under preferred terms.

    Time frame: All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.

  2. Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

    "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

    Time frame: Baseline (Pre-dose), Day 1, Day 3

  3. PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

    The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

    Time frame: Baseline (Pre-dose), Day 1, Day 3

  4. RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

    The RR interval refers to the respective time interval in the Electrocardiogram. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

    Time frame: Baseline (Pre-dose), Day 1, Day 3

  5. QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3

    The QRS interval represents the time it takes for ventricular depolarization to occur. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

    Time frame: Baseline (Pre-dose), Day 1, Day 3

  6. QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

    The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

    Time frame: Baseline (Pre-dose), Day 1, Day 3

  7. Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

    QTc interval Calc Bazett represent the interval corrected for heart rate (QTc) milliseconds (msec) which was calculated by Bazett's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

    Time frame: Baseline (Pre-dose), Day 1, Day 3

  8. Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

    QTc interval Calc Fridericia represent the interval corrected for heart rate (QTc) msec which was calculated by Fridericia's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

    Time frame: Baseline (Pre-dose), Day 1, Day 3

  9. Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3

    A significant QTc prolongation was considered when the QTc value was more than (\>) upper limit of normal (ULN) range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.

    Time frame: Baseline (Pre-dose), Day 1, Day 3

  10. Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3

    A significant QTc prolongation was considered when the QTc value was more than ULN range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.

    Time frame: Baseline (Pre-dose), Day 1, Day 3

  11. Clinical Response at Test-of-Cure (TOC) Visit

    Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported.

    Time frame: 28 to 42 days

  12. Bacteriological Response at Test-of-Cure (TOC) Visit

    Bacteriological responses were graded as presumed persistence, presumed eradication or indeterminate. 'Presumed persistence' was applicable for subjects judged to be clinical failures, and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded and invasive procedures are not warranted; índeterminate' was applicable when the bacteriological response to the study drug was not valid for any reason (eg, pre-treatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at TOC were reported.

    Time frame: 28 to 42 days

  13. Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)

    Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported

    Time frame: 28 to 42 days

  14. Clinical Response at a 'During Therapy' Visit

    Clinical responses during therapy visit were graded as clinical improvement, clinical failure, or indeterminate. Clinical improvement defined as a reduction in the severity and/or the number of signs and symptoms of infection; 'clinical failure' defined as a failure to respond or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy. 'Indeterminate' defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent, receipt of an effective concomitant antibacterial for an indication other than the study indication and receipt of less than 3 full days of study drug, etc). Percentage of subjects with clinical response during therapy visit were reported.

    Time frame: Day 3 to Day 5

  15. Bacteriological Response at a 'During Therapy' Visit

    Bacteriological response during therapy were graded as presumed persistence, presumed eradication, or indeterminate'Presumed persistence' is applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation;'presumed eradication' is defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate is applicable when the bacteriological response to the study drug is not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject is not judged a clinical failure). Percentage of subjects with bacteriological response during therapy visit were reported

    Time frame: Day 3 to Day 5

  16. Clinical Response at the End-of-Treatment (EOT) Visit

    Clinical responses at EOT were graded as resolution, failure, or indeterminate. 'Resolution' defined as a disappearance of signs and symptoms related to the infection or sufficient improvement of clinical signs and symptoms related to the infection and the subject does not require any further antibiotic therapy or surgical intervention; 'failure' defined as worsening or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy; 'indeterminate' is defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent; receipt of less than 3 full days of study drug; receipt of an effective concomitant antibacterial for an indication other than study indication; etc). Percentage of subjects with clinical response at EOT were reported.

    Time frame: Day 5 to Day 14

  17. Bacteriological Response at the End of Treatment (EOT) Visit

    Bacteriological response at EOT were grades as presumed persistence, presumed eradication or indeterminate. 'presumed persistence' was applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate' is applicable when the bacteriological response to the study drug was not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at EOT were reported.

    Time frame: Day 5 to Day 14

07

Results

Posted Dec 8, 2015

Participant flow

The study was conducted at multicenter between 21 July 2010 (first subject first visit) to 21 January 2015 (last subject last visit).

Participant flow — Overall Study
MilestoneMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Started305153
Treated301150
Completed287149
Not completed184
Withdrew: Technical problems01
Withdrew: Lost to follow-up71
Withdrew: Withdrawal by subject61
Withdrew: Protocol violation41
Withdrew: Insufficient therapeutic effect10

Outcome measures

PrimaryNumber of Subjects With Adverse Events

An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.
Reported as:
Number · Subjects
Number of Subjects With Adverse Events
SubjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Any AE17582
Any SAE206
PrimaryNumber of Subjects With Clinical Cardiac Adverse Events
Time frame:
Clinical cardiac event related to QT interval were recorded from treatment start until day 3 of treatment. All other clinical cardiac events were recorded from treatment start to test of cure visit, up to day 56.
Reported as:
Number · Subjects
Number of Subjects With Clinical Cardiac Adverse Events
SubjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Any AE387
Any SAE00
PrimaryNumber of Subjects With Musculoskeletal Adverse Events
Time frame:
All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.
Reported as:
Number · Subjects
Number of Subjects With Musculoskeletal Adverse Events
SubjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Any AE135
Any SAE10
SecondaryIncidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term

Musculoskeletal adverse events were classified as following SOCs (preferred terms): "injury, poisoning and procedural complications" (forearm fracture, joint injury, ligament sprain, muscle strain) "musculoskeletal and connective tissue disorders" (arthralgia, joint swelling, musculoskeletal pain, myalgia). Incidence rates were reported as percentage of subjects categorized under preferred terms.

Time frame:
All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.
Reported as:
Number · Percentage of subjects
Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Forearm fracture0.3 (0.01 to 1.84)0 (0 to 2.43)
Joint injury0 (0 to 1.22)0.7 (0.02 to 3.66)
Ligament sprain0.3 (0.01 to 1.84)0.7 (0.02 to 3.66)
Muscle strain0 (0 to 1.22)0.7 (0.02 to 3.66)
Arthralgia3 (1.38 to 5.6)1.3 (0.16 to 4.73)
Joint swelling0 (0 to 1.22)0.7 (0.02 to 3.66)
Musculoskeletal pain1 (0.21 to 2.88)0 (0 to 2.43)
Myalgia0.3 (0.01 to 1.84)0 (0 to 2.43)
SecondaryHeart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

"N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

Time frame:
Baseline (Pre-dose), Day 1, Day 3
Reported as:
Mean · Beats per minute (bpm)
Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
Beats per minute (bpm)Moxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Day 1: Pre-dose (N= 300, 150)93.4 ± 19.190.4 ± 16.9
Change at Day 1 ((N= 294, 148)2.8 ± 9.70.3 ± 6.9
Day 3: Pre-dose (N= 293, 146)84.3 ± 17.282.6 ± 16.2
Change at Day 3 (N= 290, 146)1 ± 8.9-0.9 ± 7.1
SecondaryPR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

Time frame:
Baseline (Pre-dose), Day 1, Day 3
Reported as:
Mean · milliseconds
PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
millisecondsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Day 1: Pre-dose (N= 299, 150)136.8294 ± 18.3554140.5933 ± 20.5113
Change at Day 1 ( N= 292, 148)0.7123 ± 8.2587-0.0203 ± 8.5631
Day 3: Pre-dose (N= 293, 146)139.4915 ± 17.3258139.5685 ± 20.8174
Change at Day 3 (N= 289, 146)1.5813 ± 9.21431.5616 ± 9.9322
SecondaryRR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

The RR interval refers to the respective time interval in the Electrocardiogram. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

Time frame:
Baseline (Pre-dose), Day 1, Day 3
Reported as:
Mean · milliseconds
RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
millisecondsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Day 1: Pre-dose (N= 300, 150)670.7567 ± 142.6153689.3067 ± 145.5957
Change at Day 1 (N= 294, 148)-20.6429 ± 74.3401-3.4797 ± 56.9955
Day 3: Pre-dose (N= 293, 146)740.4778 ± 149.0964754.6027 ± 150.1203
Change at Day 3 (N= 290, 146)-9.2862 ± 77.758210.5137 ± 67.1124
SecondaryQRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3

The QRS interval represents the time it takes for ventricular depolarization to occur. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

Time frame:
Baseline (Pre-dose), Day 1, Day 3
Reported as:
Mean · milliseconds
QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3
millisecondsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Day 1: Pre-dose (N= 300, 150)89.0333 ± 7.827988.8067 ± 7.9264
Change at Day 1 (N= 294, 148)0.119 ± 4.37991.223 ± 4.2568
Day 3: Pre-dose (N= 293, 146)89.2423 ± 8.019689.3904 ± 7.8198
Change at Day 3 (N= 289, 146)0.2768 ± 4.1230.2877 ± 3.1687
SecondaryQT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

Time frame:
Baseline (Pre-dose), Day 1, Day 3
Reported as:
Mean · milliseconds
QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
millisecondsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Day 1: Pre-dose (N= 298, 150)341.1812 ± 33.9858344.2333 ± 33.5494
Change at Day 1 (N= 290, 148)2.5828 ± 15.2131.1149 ± 11.5744
Day 3: Pre-dose (N= 292, 146)358.3082 ± 34.0504356.5822 ± 35.6653
Change at Day 3 (N= 287, 146)6.0906 ± 16.18753.1644 ± 11.9586
SecondaryCorrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

QTc interval Calc Bazett represent the interval corrected for heart rate (QTc) milliseconds (msec) which was calculated by Bazett's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

Time frame:
Baseline (Pre-dose), Day 1, Day 3
Reported as:
Mean · milliseconds
Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
millisecondsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Day 1: Pre-dose (N= 298, 150)419.5872 ± 19.3278417.34 ± 18.5718
Change at Day 1 (N= 290, 148)9.731 ± 14.29612.2905 ± 14.2544
Day 3: Pre-dose (N= 292, 146)419.2055 ± 16.6815412.7945 ± 17.0075
Change at Day 3 (N= 287, 146)9.2509 ± 16.81321 ± 12.5346
SecondaryCorrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3

QTc interval Calc Fridericia represent the interval corrected for heart rate (QTc) msec which was calculated by Fridericia's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.

Time frame:
Baseline (Pre-dose), Day 1, Day 3
Reported as:
Mean · milliseconds
Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
millisecondsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Day 1: Pre-dose (N= 298, 150)391.1846 ± 19.1574390.9467 ± 18.4339
Change at Day 1 (N= 290, 148)7.0724 ± 11.32191.9122 ± 11.3058
Day 3: Pre-dose (N= 292, 146)397.3767 ± 17.2179392.6918 ± 18.8144
Change at Day 3 (N= 287, 146)8.115 ± 13.58051.774 ± 9.3328
SecondaryPotentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3

A significant QTc prolongation was considered when the QTc value was more than (\>) upper limit of normal (ULN) range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.

Time frame:
Baseline (Pre-dose), Day 1, Day 3
Reported as:
Number · Percentage of subjects
Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Day1: Pre-dose QTcCalcFridericia>ULN (N= 300, 150)0.7 ± 19.15741.3 ± 18.4339
Day1: Post-dose QTcCalcFridericia>ULN (N= 297,148)3 ± 11.32192 ± 11.3058
Day1: Post-dose >30 ms from pre-dose (N= 297,148)2 ± 17.21790 ± 18.8144
Day1: Post-dose >60 ms from pre-dose (N= 297,148)0.3 ± 13.58050 ± 9.3328
Day3: Pre-dose QTcCalcFridericia>ULN (N= 293, 146)1.41.4
Day3: Post-dose QTcCalcFridericia>ULN (N= 291,148)9.61.4
Day3: Post-dose >30 ms from pre-dose (N= 291,148)17.93.4
Day3: Post-dose >60 ms from pre-dose (N= 291,148)1.70.7
SecondaryPotentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3

A significant QTc prolongation was considered when the QTc value was more than ULN range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.

Time frame:
Baseline (Pre-dose), Day 1, Day 3
Reported as:
Number · Percentage of subjects
Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Day1: Pre-dose QTc Calc Bazett > ULN (N= 300, 150)7.72.7
Day1: Post-dose QTc Calc Bazett > ULN (N= 297,148)16.24.1
Day1: Post-dose >30 ms from pre-dose (N= 297,148)5.40
Day1: Post-dose >60 ms from pre-dose (N= 297,148)00
Day3: Pre-dose QTc Calc Bazett > ULN (N= 293, 146)3.81.4
Day3: Post-dose QTc Calc Bazett > ULN (N= 291,148)15.53.4
Day3: Post-dose >30 ms from pre-dose (N= 291,148)9.62
Day3: Post-dose >60 ms from pre-dose (N= 291,148)0.70.7
SecondaryClinical Response at Test-of-Cure (TOC) Visit

Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported.

Time frame:
28 to 42 days
Reported as:
Number · Percentage of subjects
Clinical Response at Test-of-Cure (TOC) Visit
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Clinical Cure86.295.3
Clinical Failure5.72
Indeterminate8.12.7
SecondaryBacteriological Response at Test-of-Cure (TOC) Visit

Bacteriological responses were graded as presumed persistence, presumed eradication or indeterminate. 'Presumed persistence' was applicable for subjects judged to be clinical failures, and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded and invasive procedures are not warranted; índeterminate' was applicable when the bacteriological response to the study drug was not valid for any reason (eg, pre-treatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at TOC were reported.

Time frame:
28 to 42 days
Reported as:
Number · Percentage of subjects
Bacteriological Response at Test-of-Cure (TOC) Visit
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Presumed Persistence6.82.2
Presumed Eradication84.794.9
Indeterminate8.42.9
SecondaryClinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)

Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported

Time frame:
28 to 42 days
Reported as:
Number · Percentage of subjects
Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Clinical Cure86.295.3
Clinical Failure5.72
Indeterminate8.12.7
SecondaryClinical Response at a 'During Therapy' Visit

Clinical responses during therapy visit were graded as clinical improvement, clinical failure, or indeterminate. Clinical improvement defined as a reduction in the severity and/or the number of signs and symptoms of infection; 'clinical failure' defined as a failure to respond or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy. 'Indeterminate' defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent, receipt of an effective concomitant antibacterial for an indication other than the study indication and receipt of less than 3 full days of study drug, etc). Percentage of subjects with clinical response during therapy visit were reported.

Time frame:
Day 3 to Day 5
Reported as:
Number · Percentage of subjects
Clinical Response at a 'During Therapy' Visit
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Clinical Improvement94.398
Clinical Failure10.7
Indeterminate4.71.4
SecondaryBacteriological Response at a 'During Therapy' Visit

Bacteriological response during therapy were graded as presumed persistence, presumed eradication, or indeterminate'Presumed persistence' is applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation;'presumed eradication' is defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate is applicable when the bacteriological response to the study drug is not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject is not judged a clinical failure). Percentage of subjects with bacteriological response during therapy visit were reported

Time frame:
Day 3 to Day 5
Reported as:
Number · Percentage of subjects
Bacteriological Response at a 'During Therapy' Visit
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Presumed Persistence1.20.7
Presumed Eradication95.697.8
Indeterminate3.21.5
SecondaryClinical Response at the End-of-Treatment (EOT) Visit

Clinical responses at EOT were graded as resolution, failure, or indeterminate. 'Resolution' defined as a disappearance of signs and symptoms related to the infection or sufficient improvement of clinical signs and symptoms related to the infection and the subject does not require any further antibiotic therapy or surgical intervention; 'failure' defined as worsening or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy; 'indeterminate' is defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent; receipt of less than 3 full days of study drug; receipt of an effective concomitant antibacterial for an indication other than study indication; etc). Percentage of subjects with clinical response at EOT were reported.

Time frame:
Day 5 to Day 14
Reported as:
Number · Percentage of subjects
Clinical Response at the End-of-Treatment (EOT) Visit
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Resolution92.298
Clinical Failure4.60.7
Indeterminate3.21.4
SecondaryBacteriological Response at the End of Treatment (EOT) Visit

Bacteriological response at EOT were grades as presumed persistence, presumed eradication or indeterminate. 'presumed persistence' was applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate' is applicable when the bacteriological response to the study drug was not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at EOT were reported.

Time frame:
Day 5 to Day 14
Reported as:
Number · Percentage of subjects
Bacteriological Response at the End of Treatment (EOT) Visit
Percentage of subjectsMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Presumed Persistence5.50.7
Presumed Eradication91.197.8
Indeterminate3.41.5

Adverse events

Collected over All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moxifloxacin (Avelox, BAY12-8039)—20/301 (6.6%)127/301 (42.2%)
Comparator Ertapenem—6/150 (4%)63/150 (42%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Mechanical ileusGastrointestinal disorders3/3012/150
Abdominal abscessInfections and infestations3/3010/150
PhimosisCongenital, familial and genetic disorders0/3011/150
CellulitisInfections and infestations0/3011/150
Facial bones fractureInjury, poisoning and procedural complications0/3011/150
Generalised tonic-clonic seizureNervous system disorders0/3011/150
Idiopathic generalised epilepsyNervous system disorders0/3011/150
Intestinal obstructionGastrointestinal disorders2/3010/150
Functional gastrointestinal disorderGastrointestinal disorders2/3010/150
AnaemiaBlood and lymphatic system disorders1/3010/150
Most frequent other events
Showing 10 of 25
Most frequent other events
EventMoxifloxacin (Avelox, BAY12-8039)Comparator Ertapenem
Incision site painInjury, poisoning and procedural complications26/30114/150
Electrocardiogram QT prolongedInvestigations28/3014/150
VomitingGastrointestinal disorders20/30112/150
Procedural painInjury, poisoning and procedural complications16/30110/150
Wound infectionInfections and infestations13/3016/150
DiarrhoeaGastrointestinal disorders11/3011/150
ArthralgiaMusculoskeletal and connective tissue disorders9/3012/150
PyrexiaGeneral disorders6/3014/150
Procedural vomitingInjury, poisoning and procedural complications0/3014/150
Abdominal painGastrointestinal disorders8/3013/150

Baseline characteristics

Age, Continuous
Age, Continuous(years)Moxifloxacin (Avelox, BAY12-8039)Comparator ErtapenemTotal
Mean12.05 ± 3.6612.046 ± 3.49512.049 ± 3.602
Age, Customized
Age, Customized(Subjects)Moxifloxacin (Avelox, BAY12-8039)Comparator ErtapenemTotal
12 - < 18 years19094284
6 - < 12 years10052152
2 - < 6 years14721
3 months - < 2 years101
Sex: Female, Male
Sex: Female, Male(Participants)Moxifloxacin (Avelox, BAY12-8039)Comparator ErtapenemTotal
Female12453177
Male181100281
08

Study locations

39 sites
  • San Diego, California 92123, United States
  • Springfield, Massachusetts 01199, United States
  • Hospital de Agudos "Dr. Carlos Bocalandro"
    Tres De Febrero, Buenos Aires 1657, Argentina
  • Pleven, 5800, Bulgaria
  • Plovdiv, 4002, Bulgaria
  • Ruse, 7002, Bulgaria
  • Sofia, 1606, Bulgaria
  • Stara Zagora, 6000, Bulgaria
  • Calgary, Alberta T3B 6A8, Canada
  • Hamilton, Ontario L8N 3Z5, Canada
  • Montreal, Quebec H3H 1P3, Canada
  • Santiago, Chile
  • Olomouc, 77520, Czechia
  • Prague, 150 06, Czechia
  • Stuttgart, Baden-Württemberg 70176, Germany
  • Regensburg, Bayern 93049, Germany
  • Wuppertal, Nordrhein-Westfalen 42283, Germany
  • Athens, 115 27, Greece
  • Budapest, 1086, Hungary
  • Gyor, 9024, Hungary
  • Daugavpils, LV-5417, Latvia
  • Rezekne, LV-4601, Latvia
  • Riga, LV1004, Latvia
  • Kaunas, LT-50009, Lithuania
  • Vilnius, LT-08661, Lithuania
  • México, D.F., Distrito Federal 04530, Mexico
  • Ecatepec de Morelos, Estado De Mexico 55020, Mexico
  • Guadalajara, Jalisco C.P. 44280, Mexico
  • Cusco, Peru
  • Lima, LIMA 1, Peru
  • Lima, Peru
  • Iasi, 700309, Romania
  • Timisoara, 300011, Romania
  • Smolensk, 214019, Russian Federation
  • Vladikavkaz, 362019, Russian Federation
  • Dnipropetrovsk, 49100, Ukraine
  • Ivano-Frankovsk, 76006, Ukraine
  • Lviv, 79004, Ukraine
  • Simferopol, 95034, Ukraine
09

References and documents

Publications

  • Wirth S, Emil SGS, Engelis A, Digtyar V, Criollo M, DiCasoli C, Stass H, Willmann S, Nkulikiyinka R, Grossmann U; MOXIPEDIA Study Group. Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study. Pediatr Infect Dis J. 2018 Aug;37(8):e207-e213. doi: 10.1097/INF.0000000000001910. PubMed 29356761 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2010 to primary completion in Jan 2015, 54 months.

Results were first posted in Dec 2015, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2010
First posted
Feb 17, 2010
StartActual
Jul 21, 2010
Primary completionActual
Jan 21, 2015
CompletionActual
Jan 21, 2015
Results first posted
Dec 8, 2015
Last update
Mar 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01069900
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 17, 2010
Start date
Jul 21, 2010
Primary completion
Jan 21, 2015
Completion
Jan 21, 2015
Results posted
Dec 8, 2015
Last update
Mar 20, 2018

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion